HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer HealthCare LLC

Division of Bayer AG
www.healthcare.bayer.com

Latest From Bayer HealthCare LLC

Aleve Has A ‘Headache’ For Proprietary Brand And As First Indication On Labeled Uses List

US FDA approves Bayer HealthCare's supplemental NDA for adding Aleve Headache Pain proprietary name to use with the brand’s regular strength formulation, naproxen 220 mg. The approval also allows moving headache to top of indications list.

OTC Drugs FDA

Disclosure Of Six-Hour Limit Clears Bayer To Claim Aleve ‘Better On Pain’ Than J&J's Tylenol

An appeals panel in the BBB National Programs, Inc. industry self-regulation program said Bayer should use a "six hour" qualifier with claims that its Aleve naproxen OTC is "better on pain" than J&J's Tylenol acetaminophen products.

OTC Drugs Ad Complaints

OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies

Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.

OTC Drugs FDA

Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?

The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.

Vaccines Infectious Diseases
See All

Company Information

UsernamePublicRestriction

Register